HOME >> BIOLOGY >> NEWS
Second generation targeted antibodies - It's all in the binding

The overproduction, or 'overexpression', of the epidermal growth factor receptor (EGFR) is one of the most common aberrations in cancer, and subsequently agents that inhibit EGFR are among the most hotly-pursued potential products in the pharmaceutical industry. Now, just weeks after one of the first anti-EGFR antibodies, ImClone's Erbitux (Cetuximab), was approved for use in Europe and the USA, a 'second generation' anti-EGFR antibody is set to enter early-phase clinical trials in Australia. In two articles recently published in the Journal of Biological Chemistry, research teams from the Melbourne Branch of the international Ludwig Institute for Cancer Research (LICR) have elucidated the unique binding properties of an anti-EGFR antibody, called 806, that is able to discriminate between EGFR molecules on cancer cells and EGFR molecules on normal cells.

"There is already one anti-EGFR antibody on the market, and there are several more in clinical trials," says Dr. Andrew Scott, the Head of the LICR Melbourne Branch's Clinical Program. "Although these anti-EGFR antibodies do show some anti-tumor activity in patients, they are far from ideal because they bind to EGFR on both cancer cells and normal cells. As a result, they target normal tissues as well as the tumor, and side-effects, although mild, are common." Perhaps more importantly, the 'first generation' antibodies are limited in their clinical application and their capacity for improvement. "We need to increase the therapeutic efficacy of the available anti-EGFR antibodies," explains Dr. Scott. "What we would like to do is attach a lethal agent to an anti-EGFR antibody, such as a cytotoxic molecule or a radioisotope, so that the agent is targeted directly to the cancer cell. With the 806 antibody, we should be able to both interfere with EGFR signaling and deliver lethal agents to cancers, without causing severe side-effects through the destruction of normal, healthy cells, particularly in the liver an
'"/>

Contact: Sarah L. White, Ph.D.
swhite@licr.org
212-450-1543
Ludwig Institute for Cancer Research
6-May-2004


Page: 1 2 3

Related biology news :

1. Second call for proposals for the European Young Investigator Award
2. Secondary complications and restoration of function in SCI
3. Second EMBO International Practical Workshop for Science Teachers
4. NTP-CERHR announces the Second Phthalates Expert Panel Meeting to be held December 15-17, 1999
5. In Logged Forests, Hunting of Wildlife Becomes Deadly Second Harvest
6. Iron Supplemented Formula Milk Should Be Free For Inner City Children Into Their Second Year Of Life
7. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
8. When One Gene Has Two Roles, Its Second Function May Be Missed
9. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
10. The Second Visible Human Project Conference
11. Researchers Take A Second Look At Homocysteines Link To Heart Disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):
(Date:6/27/2017)... ... 2017 , ... The recent vote by the American Medication Association to align ... to patients and hopefully sheds new light on the way health insurers, governments and ... and founding partner of Texas Fertility Center . , “This designation is ...
(Date:6/27/2017)... ... 27, 2017 , ... According to a recent report from ... not have negative short- or long-term effects on benthic communities. , The ... located at the Puget Sound Naval Shipyard & Intermediate Maintenance Facility in Bremerton, ...
(Date:6/26/2017)... ... June 26, 2017 , ... NDA Partners Chairman Carl ... Product Development R&D at Allergan and CMC expert with more than twenty-five years ... biopharma companies, has joined the firm as an Expert Consultant. , ...
(Date:6/26/2017)... ... June 26, 2017 , ... Two new members were elected to ... June 9, 2017: Jeremy Nowak, President, J Nowak Strategy and Michele Masucci, Ph.D., Vice ... election of Glen N. Gaulton and Kenneth L. Kring, and re-election of David P. ...
Breaking Biology Technology:
Cached News: